- Home
- DEA vs GHRS Comparison
DEA vs GHRS Comparison
Compare DEA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEA | GHRS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.2M | 892.0M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DEA | GHRS |
|---|---|---|
| Price | $21.44 | $14.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $24.99 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 545.9K | 333.6K |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | ★ 8.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $334,212,000.00 | N/A |
| Revenue This Year | $9.72 | N/A |
| Revenue Next Year | $8.67 | N/A |
| P/E Ratio | $72.06 | ★ N/A |
| Revenue Growth | ★ 10.62 | N/A |
| 52 Week Low | $19.33 | $6.72 |
| 52 Week High | $29.95 | $20.50 |
Technical Indicators
Market Signals| Indicator | DEA | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 54.76 |
| Support Level | $21.58 | $13.94 |
| Resistance Level | $22.03 | $15.50 |
| Average True Range (ATR) | 0.48 | 0.85 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 56.79 | 62.50 |
Price Performance
Historical ComparisonAbout DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.